Notice of Allowance Issued for Method of Treating Cytokine Storm Using Melanocortin-Specific Peptide
Potential Broad Utility in Treating Indications Characterized by Cytokine Storm Nov 30, 2021, 07:30 ET CRANBURY, N.J., Nov. 30, 2021 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced that the U.S. Patent and …